标题
Hypertension and incident cardiovascular events following ibrutinib initiation
作者
关键词
-
出版物
BLOOD
Volume 134, Issue 22, Pages 1919-1928
出版商
American Society of Hematology
发表日期
2019-10-04
DOI
10.1182/blood.2019000840
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis
- (2019) Daniel Caldeira et al. PLoS One
- Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
- (2018) Inhye E. Ahn et al. BLOOD
- Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
- (2018) Susan O’Brien et al. BLOOD
- Safety Analysis of 4 Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
- (2018) Susan O'Brien et al. Clinical Lymphoma Myeloma & Leukemia
- Hypertension in malignancy–an underappreciated problem
- (2018) Jolanta Małyszko et al. Oncotarget
- Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies
- (2018) Avirup Guha et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib treatment improves T cell number and function in CLL patients
- (2017) Meixiao Long et al. JOURNAL OF CLINICAL INVESTIGATION
- The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages
- (2017) Lingyan Ping et al. Oncotarget
- The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
- (2016) Darryl P. Leong et al. BLOOD
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elevated plasma levels of Th17-related cytokines are associated with increased risk of atrial fibrillation
- (2016) Na Wu et al. Scientific Reports
- Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- A Randomized Trial of Intensive versus Standard Blood-Pressure Control
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells
- (2015) Gayathri Natarajan et al. OncoImmunology
- Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study
- (2015) Amirrtha Srikanthan et al. PLoS One
- Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
- (2014) J. R. McMullen et al. BLOOD
- Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells
- (2014) Wen Gao et al. JNCI-Journal of the National Cancer Institute
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Risk Score for Predicting Near-Term Incidence of Hypertension: The Framingham Heart Study
- (2013) Nisha I. Parikh et al. ANNALS OF INTERNAL MEDICINE
- 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults
- (2013) Paul A. James et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
- (2013) Ningshu Liu et al. MOLECULAR CANCER THERAPEUTICS
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
- (2010) Rebecca L Stone et al. LANCET ONCOLOGY
- Reduced Phosphoinositide 3-Kinase (p110α) Activation Increases the Susceptibility to Atrial Fibrillation
- (2009) Lynette Pretorius et al. AMERICAN JOURNAL OF PATHOLOGY
- Interleukin 17 Promotes Angiotensin II–Induced Hypertension and Vascular Dysfunction
- (2009) Meena S. Madhur et al. HYPERTENSION
- Association Between Blood Pressure Variability and Inflammatory Marker in Hypertensive Patients
- (2008) Kwang-Il Kim et al. CIRCULATION JOURNAL
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- (2008) Manuela Schmidinger et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started